Merck announces new biopharma heads for North America and China

MerckMerck, a leading science and technology company, today announced two appointments in two regions important for its biopharma business. Gary Zieziula will lead Merck's biopharma business in North America and Marc Horn will take the helm of the biopharma business in China.

Gary Zieziula (61) has been appointed President and Managing Director of the biopharma business in the U.S. and Canada, based in Rockland, Massachusetts, U.S., with immediate effect. In his role, he will be responsible for all areas of the company's business including driving overall strategic direction and maximizing growth across the region. Zieziula joined Merck in 2014 as Chief Commercial Officer in the U.S., having spent more than 30 years in the pharmaceutical industry, including senior level positions at MSD, Bristol Myers-Squibb, Roche and Amag Pharmaceuticals. Zieziula holds a Bachelor of Science degree from the State University of New York at Buffalo and an MBA from Canisius College.

"As we look to grow our biopharma business in North America, including our progress in oncology and immuno-oncology, Gary's vision, experience and customer-centric approach are critical to lead the company forward," said Simon Sturge, Chief Operating Officer at the Healthcare business of Merck, whom Zieziula will report to.

Zieziula's predecessor, Paris Panayiotopoulos, accepted a new position outside of Merck at the end of last year.

In the first nine months of 2015 net sales of Merck in North America amounted to € 1.9 billion, thereby accounting for 20% of Group sales. Healthcare sales in this region totalled € 1.1 billion in the first nine months of 2015. In the first nine months of 2015 Healthcare sales in North America represented two-thirds of Merck's total sales in the region.

Marc Horn (41) will head the biopharma business of Merck in China as of April 1, 2016, as a Managing Director based in Beijing. He is currently the regional Chief Financial Officer (CFO) of Merck responsible for Eastern Asia, comprising China, Hong Kong, Japan, South Korea and Taiwan, for the three business sectors Healthcare, Life Science and Performance Materials.

Horn has more than 16 years of management experience in finance in the pharmaceuticals and chemicals industry, including positions at Bayer and Lanxess in Germany, China and Singapore. Horn graduated from Otto-Friedrich University of Bamberg, Germany, and University of Maastricht, Netherlands, with a Master's degree in International Business Administration.

Allan Gabor, Mark Horn's predecessor, has been promoted to President of the Asian-Pacific region for Merck's biopharma business. In his new position, Horn will report to Gabor.

China is of importance to Merck currently and in future. Among others the company is building a € 80 million (650 million Yuan) pharmaceutical manufacturing plant in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region (Yangtze River Delta area). Completion of the facility, which will focus on bulk production and packaging of Glucophage, Concor and Euthyrox, is scheduled for 2016, with commercial production starting in 2017.

With an organic increase of 5.1%, sales in the Asia-Pacific region, where China is included, amounted to € 3.1 billion in the months January to September 2015. Representing a share of 33% of Group net sales, Asia-Pacific therefore became the Group's top-selling region. Healthcare sales from January to September 2015 in the Asia-Pacific region reached around € 1 billion, representing one-third of group sales in this region.

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of € 11.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

FDA approves Roche's OCREVUS™ (ocrelizumab) for re…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both ...

Read more

First collaborative definition of patient centrici…

AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-d...

Read more

High doses of vitamin C to improve cancer treatmen…

Clinical trials found that it is safe to regularly infuse brain and lung cancer patients with 800 - 1000 times the daily recommended amount of vitamin C as a potential st...

Read more

Deep learning algorithm could boost drug developme…

Artificially intelligent algorithms can learn to identify amazingly subtle information, enabling them to distinguish between people in photos or to screen medical images ...

Read more

Bristol-Myers Squibb enters into separate agreemen…

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for ...

Read more

Tagrisso (osimertinib) receives US FDA full approv…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment...

Read more

A one-two punch hits pancreatic cancer where it hu…

Australian scientists have uncovered a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumour to make it 'softer' and more respon...

Read more

FDA allows marketing of first direct-to-consumer t…

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are ...

Read more

Novartis to strengthen R&D pipeline by in-lice…

Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing condi...

Read more

New drug delivery system shows promise for fightin…

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiatio...

Read more

Towards a safe and scalable cell therapy for type …

More than 36 million people globally are affected by type 1 diabetes (T1D), a lifelong disorder where insulin producing cells are attacked and destroyed by the immune sys...

Read more

XELJANZ® (tofacitinib citrate) receives marketing …

Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination wi...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]